Furazolidone-Based Quadruple Therapy for Eradication of *Helicobacter pylori* Infection in Peptic Ulcer Disease

Rahim Raoufi Jahromi 1; Jamal Mirzaei 2; Jalil Rajabi 2,*; Seyed Javad Hoseini Shokouh 2; Taraneh Liaghat 1

1Department of Infectious Diseases, Jahrom University of Medical Sciences, Jahrom, IR Iran 2Infectious Disease Research Center, Department of Infectious Diseases, Aja University of Medical Sciences, Tehran, IR Iran

*Corresponding author: Jalil Rajabi, Infectious Disease Research Center, Aja University of Medical Sciences, Tehran, IR Iran. Tel: +98-9124450255, Fax: +98-2144066531, E-mail: rajabi_jalil@yahoo.com

Received: April 14, 2014; Accepted: May 30, 2014

**1. Background**: *Helicobacter pylori* is the main pathogenic factor for chronic gastritis and peptic ulcer disease. Therefore, its successful eradication is important in the disease management. Multiple first-line treatments have been employed; the eradication rates in the most successful regimens have been 75%-92%. Primary bacterial resistance to antibiotics and patient compliance are two main cause of therapy failure. Furazolidone with a broad spectrum of antimicrobial activities is widely used in the treatment of bacterial and protozoal infections in both humans and animals, which could also be used in treatment of *H. pylori* infection.

**Objectives**: This study was designed to evaluate the efficacy of the therapeutic regimen containing furazolidone in comparison with a standard regimen against *H. pylori*.

**Materials and Methods**: In this randomized clinical trial, 110 patients with a positive urease breath test (UBT) were selected and randomly divided into two equal groups. The first group received the standard regimen consisting of clarithromycin (500 mg Q12h), amoxicillin (1 g Q12h) and a proton pump inhibitor (PPI) (omeprazole 20 mg BID). The second group was treated with bismuth subcitrate (120 mg Q6h), furazolidone (100 mg Q6h) and tetracycline (250 mg Q6h) and a PPI (omeprazole 20 mg BID) for two weeks. UBT was performed again for all the patients two months after completing.

**Results**: UBT was negative in 83.6% of patients in the standard group two months after the end of the treatment. Eradication of *H. pylori* was reported in 94.5% of patients in the experimental group. No significant relationship between age and eradication of *H. pylori* was observed in both groups. Nausea and vomiting was reported in 5.45% of patients treated with our experimental regimen. These symptoms were tolerable and the treatment was completely continued. No adverse effect was recorded in the standard group. Moreover, no relationship was observed between gender and eradication of *H. pylori* in both groups. Finally, despite a better therapeutic response to our experimental group in comparison with the standard one, no statistically significant difference was observed (P = 0.067).

**Conclusions**: Based on our finding in this study and similar studies in different parts of the world, furazolidone could be prescribed as an effective antibiotic against *H. pylori* in patients with gastritis.

**Keywords**: Gastritis; Furazolidone; *Helicobacter pylori*

---

1. Background

There is a close relation between gastrointestinal diseases and *Helicobacter pylori*. This microorganism is the main pathogenic factor of chronic gastritis and peptic ulcer disease. In addition, the initiating factor in gastric cancer and gastric mucosa-associated lymphoid tissue lymphoma is *H. pylori* (1). Finding this microorganism as a causative agent of peptic ulcer disease (PUD) has revolutionized the scientific understanding of the condition (2). Because of the integral role of *H. pylori* in pathogenesis of PUD, its successful eradication is important in management of this disease (3-6), and substantially, the risk of ulcer recurrence and rebleeding could be reduced (3, 4). There has been a research focus to eradicate this microorganism for effective treatment of the above diseases (7). Multiple first-line treatments have been employed, and the eradication rates in the most successful regimens were from 75% to 92% (5).

There is a universal standard triple therapy with a proton pump inhibitor (PPI) or bismuth, amoxicillin and metronidazole or clarithromycin. Unfortunately, because of the widespread use of antibiotics, an increasing resistance to *H. pylori*, especially to metronidazole and clarithromycin has been resulted. “Legacy triple therapy”, recommended by the Maastricht III consensus report, has disappointingly demonstrated low success rates (i.e. below 80%) worldwide (7). Primary bacterial resistance to antibiotics and patient compliance are two main cause of therapy failure. Moreover, there are some restrictions in the use of some expensive drugs such as clarithromycin and quinolones in developing countries.
The high prevalence of H. pylori infection in adults over 35 years old (near 90%) has been shown in multiple seroprevalence studies in different parts of Iran. There has been much lower eradication rate of H. pylori in this country than the rates reported from western and developed countries. Additionally, a high rate of metronidazole resistance (37%) and an increasing rate of resistance to clarithromycin have emerged (9). Therefore, it has been suggested to use furazolidone-based treatment by the World Gastroenterology Organization and Latin America guidelines, to overcome these limitations in developing countries (10, 11). This drug is a synthetic nitrofuran with a broad spectrum of antimicrobial activities, widely used in treatment of bacterial and protozoal infections in both humans and animals (12). In spite of the low cost of the drug, some adverse effects, such as a molecule harboring a potential carcinogenic effect, might influence the drug efficacy (33-35).

2. Objectives
Increasing resistances of H. pylori to different antimicrobial drugs have encouraged scientists to find new effective therapeutic regimens. Using forgotten antimicrobial drugs in therapeutic regimens could be an effective way. In this study, the efficacy of a therapeutic regimen containing furazolidone in comparison with a standard regimen against H. pylori was evaluated.

3. Materials and Methods
In this randomized clinical trial, each patient with persistent dyspepsia, referred to Honari Clinic in Jahrom, during the period of May 2012 to June 2013, swallowed a 14C-urea capsule for Urease Breath Test (UBT) after a six-hour fasting period. Thereafter, patients laid down and changed sides every five minutes. Breath samples were collected from the subjects’ 15 minutes after the 14C-urea consumption. The samples were collected and counted using the Heliprobe method. In this method, patients swallowed a special cartridge system (Heliprobe breath card) at the 15th minute. The activities of the cartridges were counted using a small designated GM (Gelatine) counter (GM counter; Heliprobe analyzer); the presence of UBT positivity in 110 patients with positive UBT were selected. Neither of them had a history of using proton pump inhibitor (PPI) or H. pylori eradication regimens such as clarithromycin (250 mg Q6h) and a PPI (omeprazole 20 mg BID). The treatment duration in both groups was two weeks.

UBT was performed again for all the patients two months after completing the treatment to evaluate and compare the efficacy of these two regimens. Any patient with intolerance to these two regimens was excluded from the study. All the data were registered in special forms and analyzed with SPSS version 18 software using chi-square and Fisher tests and variance analysis.

4. Results
A total of 110 patients, 20-70 years old, with mean age of 36.18 ± 9.43 years old were studied. They were divided into five age groups (Table 1). Most of the patients belonged to the 30-40-year-old group (40%); 50 patients (45.5%) were male and 60 (54.5%) were female; 55 patients were treated with standard regimen for two weeks, among which, the UBT results were negative for 46 (83.6%), while it was still positive in 9 (16.4%), two months after the end of the treatment. There was no statistically significant relationship between age and eradication of H. pylori in the standard regimen group (P = 0.46). In the second group, in which 55 patients were treated with our experimental regimen, only 3 (5.5%) had positive UBT results two months after the end of the treatment and eradication of H. pylori was reported in 52 (94.5%) patients based on negative UBT results in this group. The highest eradication rate of H. pylori was reported in 30-40-year-old patients. However, there was no significant relationship between age and eradication of H. pylori in our experimental regimen group, too (P = 0.21).

There were no studies confirming the effectiveness of this drug against H. pylori. In Bahari’s study in Zahedan, Iran, a regimen containing furazolidone was more effective (85%) than another regimen without it (80%) (32). Moreover, in Talebi’s study in Iran, a regimen containing furazolidone achieved a higher rate (60%) than the other (54.3%) (33). In Talebi’s study in Iran, H. pylori resistance to different antibiotics was evaluated. In this survey, the least resistance was reported against furazolidone, tetracycline and clarithromycin, and the bacteria showed the highest resistance against metronidazole and amoxicillin (34). This high resistance rate against metronidazole was confirmed by Tigari’s study on 101 patients (35). An acceptable reason for the high rate in both groups of our study might be due to antibiotic resistance. In our study, there was no significant relationship between age and eradication of H. pylori, and eradication rate of our experimental regimen containing furazolidone was 94.5%, which was more successful than other recent similar studies in Iran (29, 30).

5. Discussion
There are some studies confirming the effectiveness of this drug against H. pylori. In Bahari’s study in Zahedan, Iran, a regimen containing furazolidone was more effective (85%) than another regimen without it (80%) (32). Moreover, in Talebi’s study in Iran, a regimen containing furazolidone achieved the most eradication rate against H. pylori and it was advised to use these medications to treat Iranian people with gastritis (36).

There are some studies confirming the effectiveness of this drug against H. pylori. In Bahari’s study in Zahedan, Iran, a regimen containing furazolidone was more effective (85%) than another regimen without it (80%) (32). Moreover, in Talebi’s study in Iran, a regimen containing furazolidone achieved the most eradication rate against H. pylori and it was advised to use these medications to treat Iranian people with gastritis (36). There are some studies confirming the effectiveness of this drug against H. pylori. In Bahari’s study in Zahedan, Iran, a regimen containing furazolidone was more effective (85%) than another regimen without it (80%) (32). Moreover, in Talebi’s study in Iran, a regimen containing furazolidone achieved the most eradication rate against H. pylori and it was advised to use these medications to treat Iranian people with gastritis (36). There are some studies confirming the effectiveness of this drug against H. pylori. In Bahari’s study in Zahedan, Iran, a regimen containing furazolidone was more effective (85%) than another regimen without it (80%) (32). Moreover, in Talebi’s study in Iran, a regimen containing furazolidone achieved the most eradication rate against H. pylori and it was advised to use these medications to treat Iranian people with gastritis (36).

The treatment duration in both groups was two weeks. Nausea and vomiting was reported in 3 (5.45%) patients in the furazolidone group. These reactions were mild and well tolerated and all the patients in that study were able to complete the entire therapy. Similarly, in Fakhri’s study, the number of patients who discontinued treatment with a furazolidone-containing regimen was not significant (20). Therefore, it could be concluded that side effects of this drug are not significant and could often be well tolerated by patients.

Based on our study and similar studies in different parts of the world, furazolidone could be prescribed as an effective antibiotic against H. pylori in patients with gastritis. However, adverse effect should be mentioned and monitored by physicians. Therefore, it could be recommended to use different antibiotics against H. pylori infection alternatively to decrease the chance of antibiotic resistance against this bacterium.

Funding/Support
This research was supported by a grant from the Infectious and Tropical Diseases Research Center of Jahrom University of Medical Sciences.

References
6. Masarrat S, Saberi-Firooz M, Sherman M. Helicobacter pylori. Management of patients with underlying peptic ulcer disease, extragastric colonization and meta-analyses (22, 23). This drug resistance could be often be well tolerated by patients.

Unfortunately, adverse effects of furazolidone may lead to interruption of treatment. This could be the main cause limiting the usage of this medication (27-30, 36). In our study, nausea and vomiting were reported in 3 (5.45%) patients who received furazolidone. This finding was similar to Ghadiri’s study results from Iran, who reported some adverse effects in 16 (7%) treated with a therapeutic regimen containing furazolidone. Their symptoms were weakness, nausea, anorexia, and dizziness (30). The use of furazolidone is often used in combination with other antimicrobials, nausea and vomiting as the most common adverse effects in the furazolidone group. These reactions were mild and well tolerated and all the patients in that study were able to complete the entire therapy. Similarly, in Fakhri’s study, the number of patients who discontinued treatment with a furazolidone-containing regimen was not significant (20). Therefore, it could be concluded that side effects of this drug are not significant and could often be well tolerated by patients.

Based on our study and similar studies in different parts of the world, furazolidone could be prescribed as an effective antibiotic against H. pylori in patients with gastritis. However, adverse effect should be mentioned and monitored by physicians. Therefore, it could be recommended to use different antibiotics against H. pylori infection alternatively to decrease the chance of antibiotic resistance against this bacterium.

Funding/Support
This research was supported by a grant from the Infectious and Tropical Diseases Research Center of Jahrom University of Medical Sciences.

References
6. Masarrat S, Saberi-Firooz M, Sherman M. Helicobacter pylori. Management of patients with underlying peptic ulcer disease, extragastric colonization and meta-analyses (22, 23). This drug resistance could be...


